Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Zoledronic acid and romosozumab sit at opposite ends of the osteoporosis pharmacology spectrum. Understanding their mechanisms clarifies why their side-effect profiles diverge so sharply.

Zoledronic acid is an aminobisphosphonate. It binds to hydroxyapatite in bone and is taken up by osteoclasts during resorption, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway 1. This triggers osteoclast apoptosis, reducing bone turnover. The drug persists in the skeleton for years after a single 5 mg IV infusion, which is both a therapeutic advantage and the reason certain adverse effects can lag behind administration.

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein secreted by osteocytes that normally suppresses the Wnt signaling pathway 2. Blocking sclerostin has a dual effect: it stimulates osteoblast-mediated bone formation while simultaneously reducing bone resorption. This "anabolic window" is unique among osteoporosis therapies. The 210 mg monthly subcutaneous injection is given for a fixed 12-month course. Because it is a large-molecule biologic rather than a small-molecule chemical, its safety profile reflects immunologic and cardiovascular pathways rather than renal clearance mechanics.

These mechanistic differences mean clinicians are not choosing between two versions of the same treatment. They are weighing an antiresorptive with a well-established 15+ year track record against a newer anabolic agent with superior fracture-reduction speed but a boxed cardiovascular warning 3.

Acute-Phase Reaction: Reclast's Most Frequent Side Effect

The acute-phase reaction (APR) after zoledronic acid infusion is the single most common adverse event reported in clinical trials. It occurs early. It is self-limiting. But it can be intense enough to deter patients from returning for their second annual dose.

In HORIZON-PFT (N=7,765), 31.6% of zoledronic acid recipients reported an APR within three days of the first infusion, compared with 6.2% on placebo 1. Symptoms include fever, myalgia, arthralgia, headache, and influenza-like illness. The reaction is driven by transient release of pro-inflammatory cytokines (TNF-alpha, IL-6, interferon-gamma) from gamma-delta T cells exposed to accumulated isopentenyl pyrophosphate 4. Symptom onset typically peaks at 24 to 72 hours and resolves within three days.

The good news: APR incidence drops dramatically with subsequent infusions. By the second annual dose in HORIZON-PFT, only 6.6% reported APR symptoms 1. Pre-treatment with acetaminophen 650 mg or ibuprofen 400 mg before and for 72 hours after infusion reduces both incidence and severity, as noted in the Endocrine Society's 2020 guidelines [5]. Adequate hydration before infusion is also recommended.

Romosozumab, by contrast, does not cause acute-phase reactions. Its most common systemic complaints in ARCH (N=4,093) were arthralgia (12.4% vs 10.6% on alendronate) and headache (4.0% vs 2.9%), neither of which showed the acute post-dose temporal clustering seen with zoledronic acid 2.

Cardiovascular Safety: Evenity's Boxed Warning

This is the most consequential difference between these two drugs from a safety standpoint. The FDA placed a boxed warning on romosozumab in April 2019, the most serious type of drug safety label.

In the ARCH trial, serious cardiovascular events (adjudicated as myocardial infarction, stroke, or cardiovascular death) occurred in 2.5% of romosozumab-treated patients (50 of 2,040) versus 1.9% of alendronate-treated patients (38 of 2,014) over 12 months 2. The absolute difference was 0.6%, yielding an odds ratio of 1.31. The signal was concentrated in the first 12 months of romosozumab exposure.

The FDA label now states: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" 3.

Zoledronic acid has no comparable cardiovascular signal. HORIZON-PFT actually reported a possible reduction in all-cause mortality with zoledronic acid in the recurrent fracture trial (HORIZON-RFT), though this finding was exploratory and not replicated in a dedicated cardiovascular outcomes study 6.

The mechanism behind romosozumab's cardiovascular signal remains debated. Sclerostin is expressed in vascular smooth muscle and aortic valve tissue. Patients with sclerosteosis (a genetic condition of absent sclerostin) do not show excess cardiovascular disease, which has led some researchers to question whether the signal is drug-related or a statistical artifact of the ARCH comparator arm 7. The FRAME trial (romosozumab vs placebo, N=7,180) did not show a cardiovascular imbalance 8. Still, the boxed warning stands, and pre-treatment cardiovascular risk assessment is now standard practice.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Romosozumab should be avoided in patients with recent (within 1 year) cardiovascular event, and the cardiovascular risk-benefit should be carefully considered in all patients" 9.

Injection-Site and Administration Reactions

The route of administration shapes the day-to-day tolerability experience for each drug.

Zoledronic acid is given as a 5 mg IV infusion over at least 15 minutes, once per year. The infusion itself is generally well tolerated when delivered at appropriate speed. Rapid infusion (under 15 minutes) has been linked to renal toxicity, which is why the minimum infusion time is strictly enforced 10. Some patients report transient taste disturbance during the infusion. Local infusion-site reactions (redness, swelling) occur in approximately 0.7% of patients 1.

Romosozumab requires two subcutaneous injections of 105 mg each (total 210 mg) administered in the abdomen, thigh, or upper arm every month for 12 months. That amounts to 24 injections total over the treatment course. Injection-site reactions (pain, erythema, bruising) were reported in 5.2% of romosozumab patients in ARCH versus 2.9% with alendronate 2. These reactions are generally mild and do not typically lead to treatment discontinuation.

Patient preference data suggest that the once-yearly convenience of zoledronic acid is strongly favored over monthly injections for adherence. A preference study published in Osteoporosis International found that 76% of postmenopausal women preferred annual IV dosing over monthly oral or injectable regimens when efficacy was held constant 11. However, romosozumab's fixed 12-month course means the injection burden is time-limited rather than indefinite.

Renal Safety

Renal function is a critical differentiator. This matters especially in elderly osteoporosis patients, who often have declining kidney function.

Zoledronic acid is cleared renally and is contraindicated in patients with creatinine clearance <35 mL/min. Cases of acute renal failure, including some requiring dialysis, have been reported, particularly with rapid IV infusion or in patients with pre-existing renal impairment 10. The FDA label requires serum creatinine measurement before each dose. In HORIZON-PFT, transient creatinine elevations (>0.5 mg/dL above baseline) occurred in 1.3% of zoledronic acid patients versus 0.4% on placebo 1. Most resolved within 30 days.

Romosozumab, as a monoclonal antibody, is not cleared through the kidneys. No dose adjustment is required for renal impairment. The FRAME and ARCH trials did not exclude patients based on renal function, and no renal toxicity signal emerged 2. This makes romosozumab a practical option for patients with moderate to severe chronic kidney disease who are otherwise poor candidates for bisphosphonates, though mineral metabolism should be monitored in advanced CKD (stages 4 and 5).

Rare but Serious Skeletal Adverse Events

Both drugs carry label warnings for osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). These events are rare in the osteoporosis population and far more common in oncology dosing of zoledronic acid (4 mg IV every 3 to 4 weeks).

For zoledronic acid at the osteoporosis dose (5 mg once yearly), the estimated ONJ incidence is approximately 1 in 10,000 to 1 in 100,000 patient-years 12. AFF risk increases with cumulative bisphosphonate exposure beyond 5 years, which is why drug holidays are recommended after 3 to 6 years for non-high-risk patients per the ASBMR task force recommendations [13].

For romosozumab, ONJ and AFF have been reported in postmarketing surveillance, but incidence rates are difficult to calculate given shorter market exposure. The 12-month treatment cap may inherently limit cumulative skeletal risk. In ARCH, no confirmed AFF cases were reported in the romosozumab group during the 12-month treatment period, though two possible cases emerged in the subsequent alendronate phase 2.

Clinicians should perform dental examinations before initiating either drug, avoid invasive dental procedures during treatment when possible, and educate patients about prodromal thigh or groin pain that might signal AFF.

Hypocalcemia Risk

Both drugs can precipitate hypocalcemia, and both labels mandate adequate calcium and vitamin D supplementation before starting treatment.

Zoledronic acid's rapid suppression of osteoclast activity can lower serum calcium within 24 to 48 hours of infusion. In HORIZON-PFT, 0.2% of patients on zoledronic acid developed grade 3 hypocalcemia (albumin-corrected calcium <7.5 mg/dL), compared with 0.1% on placebo 1. Risk is higher in patients with vitamin D deficiency, malabsorption syndromes, or concurrent renal impairment.

Romosozumab's dual mechanism (increasing formation while reducing resorption) creates a net calcium demand from new bone mineralization. In FRAME, mean serum calcium decreased transiently in the first month and returned to baseline by month 3 in most patients 8. The clinical hypocalcemia rate was not significantly different from placebo. Patients with baseline 25-hydroxyvitamin D levels below 20 ng/mL should be repleted before starting either agent.

Immunogenicity: A Consideration for Romosozumab

As a monoclonal antibody, romosozumab can trigger anti-drug antibody (ADA) formation. In the FRAME trial, 18.1% of romosozumab-treated patients developed binding antibodies, and 0.7% developed neutralizing antibodies 8. In patients with neutralizing antibodies, bone mineral density gains were numerically lower, though the sample size was too small for statistical conclusions.

Zoledronic acid, being a small synthetic molecule, does not provoke an immune response. No immunogenicity testing is relevant.

This distinction rarely changes prescribing decisions in practice, but it may become clinically meaningful if a patient requires retreatment with romosozumab after a gap or if future sclerostin inhibitors enter development.

Discontinuation and Rebound Effects

What happens after stopping each drug is itself a safety consideration.

Zoledronic acid's prolonged skeletal binding provides a residual antiresorptive effect for months to years after the last dose. Bone turnover markers rise slowly, and bone mineral density declines gradually. This pharmacokinetic "tail" is the basis for the bisphosphonate drug holiday concept 13. There is no abrupt rebound in fracture risk.

Romosozumab's effect wanes quickly after the 12th dose. Bone formation markers return to baseline within 3 months, and bone resorption markers actually overshoot pre-treatment levels temporarily. If no antiresorptive agent is started after romosozumab, the BMD gains are substantially lost within 12 to 24 months 14. This is not a "side effect" in the traditional sense, but it is a clinically relevant safety consideration: patients must have a clear transition plan to a bisphosphonate or denosumab after completing romosozumab.

The ARCH trial protocol transitioned all romosozumab patients to alendronate at month 12, and the BMD gains were not only maintained but continued to increase through month 36 2.

Which Patients Should Avoid Which Drug

The side-effect profiles create clear clinical contraindications that simplify the decision for many patients.

Avoid zoledronic acid in patients with CrCl <35 mL/min, known hypersensitivity to bisphosphonates, uncorrected hypocalcemia, or those who cannot tolerate the APR despite premedication. Use particular caution in patients on concurrent nephrotoxic medications (aminoglycosides, loop diuretics at high doses, NSAIDs).

Avoid romosozumab in patients who have had a myocardial infarction or stroke within the preceding 12 months. Use caution in patients with multiple cardiovascular risk factors, those with known hypersensitivity to romosozumab or any excipient, and patients who cannot commit to transitioning to an antiresorptive after the 12-month course 9.

For postmenopausal women with very high fracture risk, normal renal function, and low cardiovascular risk, the AACE guidelines recommend romosozumab as a first-line anabolic option followed by antiresorptive consolidation. For patients with renal impairment or cardiovascular history, zoledronic acid (if renal function permits) or denosumab may be preferable 5.

A baseline ECG is not required before either drug, but a cardiovascular risk assessment using standard tools (e.g., ACC/AHA ASCVD risk calculator) is reasonable before prescribing romosozumab, particularly in women over 70 with hypertension, diabetes, or dyslipidemia.